Iti-214 (DrugBank: ITI-214)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03257046 (ClinicalTrials.gov) | September 28, 2017 | 14/8/2017 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease | A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: ITI-214;Other: Placebo | Intra-Cellular Therapies, Inc. | NULL | Completed | 50 Years | N/A | All | 40 | Phase 1;Phase 2 | United States |